Previous 10 | Next 10 |
3 Cheap Penny Stocks to Watch in August 2022 If you’re looking for penny stocks to buy right now, there are a few things you should keep in mind. For one, right now, there is a lot of volatility in the stock market. This means that stocks are going up and down in valu...
CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first patient has been dosed in its Phase 3 study evaluati...
CARLSBAD, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the closing of its previously announced underwritten public offering for...
Palisade Bio press release ( NASDAQ: PALI ): Q2 GAAP EPS of -$0.12. As of June 30, 2022, the company had cash and cash equivalents of $5M For further details see: Palisade Bio GAAP EPS of -$0.12
CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications (the “Company”), reported its financial results for the quarter ended Ju...
Palisade Bio ( NASDAQ: PALI ) shares dropped over -34% pre-market on Friday after the biopharmaceutical company priced its ~$12M securities offering . The offering consists of 42.16M shares of common stock, 1,460 shares of Series B convertible preferred stock, 48M Seri...
CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the pricing of an underwritten public offering for gross proceeds of app...
Palisade Bio ( NASDAQ: PALI ) said on Monday it had launched its new corporate website, palisadebio.com. The company also reiterated its commitment to develop therapeutics that protect intestinal barrier health. Its lead product candidate, LB1148, is an oral liquid for...
CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the launch of its new corporate website, palisadebio.com and rei...
Palisade Bio ( NASDAQ: PALI ) said on Wednesday the first patient had been screened in a Phase 3 study testing its drug, LB1148, to help return bowel function in adult patients undergoing gastrointestinal surgery. The company said it was working to enroll patients and ...
News, Short Squeeze, Breakout and More Instantly...
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition o...
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Ph...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...